Abcam, ab258988, Human NCOA7 knockout A549 cell lysate

Size: 1Kit
NCOA7 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon11 and 35 bp insertion in exon11.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon11 and 35 bp insertion in exon11.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-NCOA7, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Nuclear receptor coactivator 7 (NCOA7) also known as ERAP plays a role in transcriptional regulation by interacting with nuclear hormone receptors to enhance their transcriptional activity. It has a molecular mass of approximately 100 kDa. NCOA7 is expressed in various tissues with significant levels in the brain and endocrine organs. The protein influences the transcriptional activity of hormone receptors by modulating chromatin structure and accessibility.
Biological function summary
NCOA7 influences cellular processes through interactions with nuclear receptors. It forms a complex with these receptors to modulate gene expression. This protein engages in the regulation of genes that are involved in cell development and homeostasis. NCOA7's activity can influence metabolic and signaling processes that are critical for maintaining proper cellular environment and function.
Pathways
NCOA7 associates with important biological pathways including nuclear hormone receptor signaling and lipid metabolism. It interacts with proteins like peroxisome proliferator-activated receptors (PPARs) and estrogen receptors (ERs) in these pathways. These interactions facilitate the regulation of genes involved in lipid storage energy balance and other metabolic functions.
NCOA7 has implications in conditions such as breast cancer and neurodegenerative diseases. In breast cancer its interaction with estrogen receptors can influence tumor growth and development. NCOA7 is also connected to conditions like Alzheimer's disease through its influence on brain tissues potentially interacting with proteins like amyloid-beta precursor protein which is relevant to the disease pathology.